Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HUTCHMED (China)HMDCF 71 Days Sales Outstanding is 80.11 as of Jun. 2026, which is 15% above its 10-year median of 69.71. GuruFocus rates HMDCF with a GF Score™ of 71/100 and a GF Value™ of $2.50. The stock has 8 warning signs investors should review. Among 950 Drug Manufacturers companies, HUTCHMED (China) ranks worse than 70% on this metric.
HUTCHMED (China) (OTCPK:HMDCF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
HUTCHMED (China) Days Sales Outstanding Related Terms
HUTCHMED (China) Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for HUTCHMED (China)'s Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HMDCF vs ZTS, UTHR, VTRS: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, HUTCHMED (China)'s Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HUTCHMED (China) Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, HUTCHMED (China)'s Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where HUTCHMED (China)'s Days Sales Outstanding falls into.
HUTCHMED (China) Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HUTCHMED (China) (HMDCF) has a Days Sales Outstanding of 80.11 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on HUTCHMED (China) and its competitors. This is 15% above median its historical median of 69.71. Over the past decade, HUTCHMED (China)'s Days Sales Outstanding has ranged from 47.63 to 96.97. According to the industry distribution chart, HUTCHMED (China) ranks #665 out of 950 companies in the Drug Manufacturers industry, placing it in the top 70%.
Is HUTCHMED (China)'s Days Sales Outstanding too high?
HUTCHMED (China)'s current Days Sales Outstanding of 80.11 is 15% above median its 10-year median of 69.71. Over the past 10 years, this metric has ranged from a low of 47.63 to a high of 96.97. The Drug Manufacturers industry median Days Sales Outstanding is 72.16. HUTCHMED (China)'s value of 80.11 is 11% above this industry median. Based on the distribution chart, HUTCHMED (China) ranks #665 out of 950 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, HUTCHMED (China) has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does HUTCHMED (China)'s Days Sales Outstanding compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, HUTCHMED (China) ranks #665 out of 950 companies for Days Sales Outstanding. This places HUTCHMED (China) in the lower half of its industry. The industry median Days Sales Outstanding is 72.16. HUTCHMED (China)'s value of 80.11 is 11% above this benchmark. Historically, HUTCHMED (China)'s own Days Sales Outstanding has ranged from 47.63 to 96.97 over the past decade. While the company's 10-year median is 69.71 vs. the industry median of 72.16, HUTCHMED (China) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 72.16, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HUTCHMED (China)'s current Days Sales Outstanding of 80.11 is 11% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on HUTCHMED (China) and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 72.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HUTCHMED (China)'s current Days Sales Outstanding is 80.11, which is 15% above median its own 10-year median of 69.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HUTCHMED (China) stock overvalued right now?
HUTCHMED (China) (HMDCF) has a current Days Sales Outstanding of 80.11. The stock's GF Value™ is $2.50, compared to a current price of $2.16 — trading 13.6% below its estimated fair value. The current Days Sales Outstanding is 80.11, which is 15% above median its 10-year median of 69.71 and 11% above the Drug Manufacturers industry median of 72.16. HUTCHMED (China)'s overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For HUTCHMED (China) (HMDCF), the current Days Sales Outstanding is 80.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HUTCHMED (China) (HMDCF) Overvalued in 2026?
Based on GuruFocus' analysis, HUTCHMED (China) stock appears to be undervalued.
The current stock price of $2.16 is trading 13.6% below its estimated GF Value™ of $2.50.
Key valuation signals for HMDCF:
Days Sales Outstanding: 80.11 (15% above median its 10-year median of 69.71)
GF Value™: $2.50 vs. price of $2.16 (13.6% below fair value)
Industry Position: 11% above the Drug Manufacturers median (#665 of 950)
No single metric tells the full story. See the HMDCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
71GF Score
Get the complete analysis for HMDCF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HMDCF has been successfully added to your 
